Cargando…

Correcting for selection bias in two-stage trials with multiple correlated outcomes: application to seamless phase ii/iii clinical trials

Detalles Bibliográficos
Autores principales:	Robertson, David, Prevost, A Toby, Bowden, Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660106/ http://dx.doi.org/10.1186/1745-6215-16-S2-P145

Ejemplares similares

Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules
por: Robertson, David S., et al.
Publicado: (2016)

The importance of planning for a seamless transition in an adaptive phase II randomised trial
por: Marshall, Andrea, et al.
Publicado: (2011)

Estimation bias in survival data within clinical trials that use adaptive seamless designs
por: Khan, Josephine, et al.
Publicado: (2015)

An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information
por: Stallard, Nigel
Publicado: (2011)

Correcting for bias in the selection and validation of informative diagnostic tests
por: Robertson, David S, et al.
Publicado: (2015)

Optimizing the data combination rule for seamless phase II/III clinical trials
por: Hampson, Lisa V, et al.
Publicado: (2015)

Accounting for selection and correlation in the analysis of two-stage genome-wide association studies
por: Robertson, David S., et al.
Publicado: (2016)

Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial
por: Hall, Peter, et al.
Publicado: (2015)

A gated group sequential design for seamless Phase II/III trial with subpopulation selection
por: Miao, Guanhong, et al.
Publicado: (2023)

Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
por: Palermos, Dionysios, et al.
Publicado: (2022)

A Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis
por: Whitehead, Anne, et al.
Publicado: (2011)

Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data
por: Kunz, Cornelia Ursula, et al.
Publicado: (2014)

Designing a preliminary adaptive study to inform a biomarker trial in Psoriasis
por: Prevost, Andrew T, et al.
Publicado: (2011)

Using meta-analysis of Phase II trials to predict Phase III trial results
por: Burke, Danielle, et al.
Publicado: (2013)

Experiences in the design and implementation of phase II trials in CLL
por: Cohen, Dena R, et al.
Publicado: (2011)

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
por: Lapointe, Réjean, et al.
Publicado: (2015)

Phase II trial designs for complex interventions: a single-arm single-stage design for clustered continuous outcomes
por: Wilson, Duncan T, et al.
Publicado: (2015)

Immunoscore(®) as a predictor of response to chemotherapy in stage II and stage III colon cancer
por: Mlecnik, Bernhard, et al.
Publicado: (2015)

Correction: A Novel Bayesian Seamless Phase I/II Design
por: Pan, Haitao, et al.
Publicado: (2013)

A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints
por: Kunz, Cornelia Ursula, et al.
Publicado: (2015)

Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
por: Duputel, Benjamin, et al.
Publicado: (2023)

Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
por: Wilgenhof, Sofie, et al.
Publicado: (2015)

Revisiting the multi-armed bandit model for the optimal design of clinical trials: benefits and drawbacks
por: Villar, Sofia S, et al.
Publicado: (2013)

A probability of benefit (AUC) approach to phase II cancer trials
por: Silcocks, Paul
Publicado: (2015)

Software tools for implementing simulation studies in adaptive seamless designs: introducing R package ASD
por: Parsons, Nick, et al.
Publicado: (2011)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
por: Long, Georgina V, et al.
Publicado: (2015)

Exploring non-compliance in a cluster randomised feasibility study to inform the design of the phase III trial
por: Bell, Lauren, et al.
Publicado: (2015)

A discussion of an issue relating to sample sizes of exact phase II trial designs
por: Howman, Andrew
Publicado: (2013)

Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer
por: Subudhi, Sumit K, et al.
Publicado: (2015)

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
por: Kaufman, Howard L, et al.
Publicado: (2014)

Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014)

Development of a method for adjusting trial results for biases in meta-analysis
por: Turner, Rebecca, et al.
Publicado: (2013)

New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
por: Penezina, O, et al.
Publicado: (2012)

Design, method and application of stopping rules in a phase III 2x2 factorial randomised controlled trial
por: Bowers, Megan, et al.
Publicado: (2015)

The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints
por: Jackson, Richard, et al.
Publicado: (2013)

Modifying the multi-arm multi-stage (MAMS) design for use in a phase II tuberculosis trial in sub-Saharan Africa with a time-to-event primary outcome
por: Phillips, Patrick, et al.
Publicado: (2013)

Early phase clinical trials in oncology: realising the potential of seamless designs
por: Jaki, Thomas, et al.
Publicado: (2023)

Enrolment and logistical challenges in TaMoVac 01 Phase I/II HIV trial despite the completion of an earlier (HIVIS-03 trial trial) in Dar es Salaam
por: Ngatoluwa, M, et al.
Publicado: (2012)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

Phase III randomised chemoprevention study of Selenium on the recurrence of non-invasive bladder cancer. The SELEnium and BLAdder cancer Trial (SELEBLAT)
por: Goossens, Maria (Mieke), et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3ku1lm8600863783k1kul4frs2